Shattuck Labs (NASDAQ:STTK) Upgraded to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Shattuck Labs (NASDAQ:STTK) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

Separately, Leerink Partners started coverage on shares of Shattuck Labs in a research note on Monday. They set an “outperform” rating and a $4.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Stock Performance

Shares of STTK opened at $1.16 on Monday. The company has a market capitalization of $55.38 million, a price-to-earnings ratio of -0.76 and a beta of 1.66. The company’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.60. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76.

Hedge Funds Weigh In On Shattuck Labs

A number of large investors have recently bought and sold shares of the stock. Prosight Management LP raised its stake in Shattuck Labs by 15.1% during the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after purchasing an additional 873,409 shares during the period. Millennium Management LLC raised its stake in Shattuck Labs by 37.0% during the fourth quarter. Millennium Management LLC now owns 201,214 shares of the company’s stock worth $243,000 after purchasing an additional 54,322 shares during the period. Deutsche Bank AG raised its stake in Shattuck Labs by 476.4% during the fourth quarter. Deutsche Bank AG now owns 116,868 shares of the company’s stock worth $141,000 after purchasing an additional 96,594 shares during the period. Bank of America Corp DE raised its stake in Shattuck Labs by 135.0% during the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after purchasing an additional 107,491 shares during the period. Finally, 683 Capital Management LLC purchased a new position in Shattuck Labs during the fourth quarter worth approximately $1,270,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.